Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML
A Phase Ib Study of Liposomal Mitoxantrone Combined With Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit Patients With Acute Myeloid Leukemia
This prospective, open-label, multicenter phase Ib trial will evaluate the safety, tolerability, and RP2D of the VAM regimen (liposomal mitoxantrone + azacitidine [AZA] + venetoclax [VEN]) in elderly or unfit patients with newly diagnosed AML. A standard 3+3 dose escalation will enroll 12-30 patients, testing liposomal mitoxantrone at 8, 12, 16, and 20 mg/m². VEN duration (9 vs. 14 days) will be determined at the 8 mg/m² dose level, after which only liposomal mitoxantrone will be escalated while AZA and VEN will remain fixed.
Induction therapy will consist of up to two 28-day cycles. Responders achieving CR/CRi/MLFS will be eligible for up to 4 consolidation cycles (total ≤6 cycles), after which they will proceed to maintenance with either AZA+VEN or observation.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 1
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Kuvaus
Inclusion Criteria:
Subjects eligible for enrollment in this study must meet all of the following criteria:
- Diagnosis of acute myeloid leukemia (AML) according to the WHO 2022 or ICC criteria, excluding acute promyelocytic leukemia (APL).
- No prior therapy for AML, except hydroxyurea for the management of hyperleukocytosis.
Meeting at least one of the following criteria:
- Age ≥ 75 years;
- Age 18-74 years with at least one of the following conditions precluding suitability for intensive chemotherapy:
i. ECOG performance status 2-3; ii. Cardiac dysfunction with left ventricular ejection fraction (LVEF) ≤ 50%; iii. Pulmonary dysfunction with diffusing capacity of the lung for carbon monoxide (DLCO) ≤ 65% or forced expiratory volume in 1 second (FEV1) ≤ 65%; iv. Creatinine clearance 30-45 mL/min; v. Other major organ dysfunction or comorbidities that, in the investigator's judgment, render the patient unsuitable for intensive chemotherapy.
- ECOG performance status 0-3.
- Life expectancy ≥ 3 months.
- Patients of childbearing potential agree to use effective contraception during the treatment period and for at least 6 months after the last dose of study treatment.
- Voluntary written informed consent provided.
Exclusion Criteria:
Subjects who meet any of the following criteria will not be eligible for enrollment in this study:
- Acute promyelocytic leukemia (APL)..
- Active central nervous system (CNS) leukemia.
- Prior targeted therapy or chemotherapy for AML, excluding hydroxyurea.
- Uncontrolled active infection.
- Uncontrolled cardiovascular disease: New York Heart Association (NYHA) class III-IV heart failure, myocardial infarction or unstable angina within 6 months before enrollment, or uncontrolled hypertension.
- Left ventricular ejection fraction (LVEF) < 40%.
- Concurrent active malignancy, except for cured non-melanoma skin cancer, carcinoma in situ of the cervix, or localized prostate cancer.
- Known hypersensitivity to the study drugs or their excipients.
- Pregnant or breastfeeding women.
- Any other condition that, in the investigator's judgment, would make the patient unsuitable for study participation.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Venetoclax, azacitidine combined with liposome mitoxantrone as induction regimen
The trial will employ a standard 3+3 dose escalation design, testing liposomal mitoxantrone at 8, 12, 16, and 20 mg/m². VEN duration (9 vs. 14 days) will be determined at the 8 mg/m² dose level, after which only liposomal mitoxantrone will be escalated while AZA and VEN will remain fixed. Venetoclax duration will be sequentially escalated (9 vs. 14 days), choosing the longest duration without dose-limiting toxicity (DLT) in 3-6 evaluable patients. The RP2D for liposomal mitoxantrone is the highest dose with ≤1 DLT in 6 patients; if DL4 is tolerated, RP2D = 20 mg/m² on day 1. |
Liposome Mitoxantrone: 8, 12, 16, and 20 mg/m², administered by intravenous drip (ivgtt) on day 1, every 4 weeks
Venetoclax(9 days): 100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-9, administered orally (po), every 4 weeks Venetoclax(14 days): 100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-14, administered orally (po), every 4 weeks
Azacitidine: 75 mg/m², administered subcutaneously (sc) on days 1-7, every 4 weeks
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Dose-Limiting Toxicity (DLT)
Aikaikkuna: Cycle 1(up to 42 days)
|
To evaluate the safety, tolerability, and RP2D of the VAM regimen in newly diagnosed elderly/unfit AML patients.
|
Cycle 1(up to 42 days)
|
|
Incidence of treatment-related adverse events
Aikaikkuna: From day 1 of treatment to 28 days after the last dose
|
The safety of the drug was evaluated by NCI-CTC AE 5.0 standard which including hematologic and non-hematologic toxicity
|
From day 1 of treatment to 28 days after the last dose
|
|
Composite complete remission (CRc) rate
Aikaikkuna: Up to approximately eight weeks
|
Proportion of patients with complete remission (CR), complete remission with incomplete hematologic recovery (CRi) or morphologic leukemia-free state (MLFS)
|
Up to approximately eight weeks
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Complete remission (CR) rate
Aikaikkuna: Up to approximately eight weeks
|
Proportion of patients with complete remission (CR)
|
Up to approximately eight weeks
|
|
Complete remission with incomplete hematologic recovery (CRi) rate
Aikaikkuna: Up to approximately eight weeks
|
Proportion of patients with complete remission with incomplete hematologic recovery (CRi)
|
Up to approximately eight weeks
|
|
Morphologic leukemia-free state (MLFS) rate
Aikaikkuna: Up to approximately eight weeks
|
Proportion of patients with morphologic leukemia-free state (MLFS)
|
Up to approximately eight weeks
|
|
Event-free survival (EFS)
Aikaikkuna: Up to approximately 5 years
|
It is defined as the time from the start of study treatment to the occurrence of induction failure or disease progression or death from any cause (whichever occurs first)
|
Up to approximately 5 years
|
|
Overall survival (OS)
Aikaikkuna: Up to approximately 5 years
|
It is defined as the time from the start of study treatment to the death from any cause
|
Up to approximately 5 years
|
|
Relapse-free Survival (RFS)
Aikaikkuna: Up to approximately 5 years
|
It is defined as the time from the start of achieving remission to disease progression, death from any cause or the last follow-up
|
Up to approximately 5 years
|
|
Duration of Response (DoR)
Aikaikkuna: Up to approximately 5 years
|
It is defined as the time from the first documentation of CRc to relapse
|
Up to approximately 5 years
|
|
30-day postinduction mortality
Aikaikkuna: Up to approximately 30 days
|
It is defined as death from any cause within 30 days after the start of induction
|
Up to approximately 30 days
|
|
60-day postinduction mortality
Aikaikkuna: Up to approximately 60 days
|
t is defined as death from any cause within 60 days after the start of induction
|
Up to approximately 60 days
|
|
Measurable Residual Disease (MRD) negative rate by flow cytometry
Aikaikkuna: Up to approximately eight weeks
|
Among those who have achieved CR/CRh/CRi after induction, proportion of patients who is MRD-negative by flow cytometry
|
Up to approximately eight weeks
|
|
Measurable Residual Disease (MRD) negative rate by molecular testing
Aikaikkuna: Up to approximately eight weeks
|
Among those who have achieved CR/CRh/CRi after induction, proportion of patients who is MRD-negative by molecular testing
|
Up to approximately eight weeks
|
Yhteistyökumppanit ja tutkijat
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Neoplasmat
- Neoplasmat histologisen tyypin mukaan
- Hematologiset sairaudet
- Leukemia, myeloidi
- Leukemia
- Hemic- ja imusuutteet
- Leukemia, myelooinen, akuutti
- Orgaaniset kemikaalit
- Heterosykliset yhdisteet, 1-rengas
- Heterosykliset yhdisteet
- Nukleiinihapot, nukleotidit ja nukleosidit
- Syytidiini
- Pyrimidiininnukleosidit
- Pyrimidiinit
- AZA -yhdisteet
- Nukleosidit
- Ribonukleosidit
- Atsasitidiini
- Venetoclax
Muut tutkimustunnusnumerot
- IIT2026104
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .